Characteristica | Men (N=507) | Women (N=405) | P | Overall (N=913) |
---|---|---|---|---|
Age (years) | ||||
Median [IQR] | 33 [29 – 38] | 32 [27 – 37] | 0.003 | 32 [28 – 38] |
WHO clinical stage | ||||
Stage 4 | 316 (62.3%) | 215 (53.1%) | < 0.001 | 531 (58.2%) |
Stage 3 | 143 (28.2%) | 117 (28.9%) | 261 (28.6%) | |
Stage 2 | 35 (6.9%) | 44 (10.9%) | 79 (8.6%) | |
Stage 1 | 13 (2.6%) | 29 (7.1%) | 42 (4.6%) | |
CD4 cell count (cells/μL) b | ||||
Median [IQR] | 41 [12 – 130] | 65 [20 – 166] | 0.002 | 49 [15 – 148] |
< 50 | 236 (55.3%) | 155 (44.7%) | 391 (50.5%) | |
50-199 | 144 (33.7%) | 133 (38.3%) | 278 (35.9%) | |
≥ 200 | 47 (11.0%) | 59 (17.0%) | 106 (13.6%) | |
Body mass index (kg/m 2 ) c | ||||
Median [IQR] | 18.7 [17.1 – 20.7] | 18.2 [16.4 – 20.5] | 0.07 | 18.5 [16.8 – 20.6] |
Haemoglobin level (g/dL) d | ||||
Median [IQR] | 11.6 [9.9 – 13.2] | 11.3 [9.6 – 12.7] | 0.07 | 11.4 [9.7 – 13.1] |